Daily Ards Research Analysis
Across two studies, one mechanistic paper identifies RACK1 as a druggable chaperone of NLRP3 inflammasome activation and shows that a covalent small molecule (bigelovin) mitigates lung injury in murine ARDS. A prospective neonatal study attempting bedside L/S ratio testing using gastric aspirates could not disclose diagnostic accuracy and highlights feasibility barriers that limit clinical applicability.
Summary
Across two studies, one mechanistic paper identifies RACK1 as a druggable chaperone of NLRP3 inflammasome activation and shows that a covalent small molecule (bigelovin) mitigates lung injury in murine ARDS. A prospective neonatal study attempting bedside L/S ratio testing using gastric aspirates could not disclose diagnostic accuracy and highlights feasibility barriers that limit clinical applicability.
Research Themes
- Inflammasome-targeted therapeutics for ARDS
- Point-of-care diagnostics in neonatal respiratory care
- Translational barriers from preclinical discovery to bedside
Selected Articles
1. Inhibition of RACK1-Mediated NLRP3 Oligomerization (Active Conformation) Ameliorates Acute Respiratory Distress Syndrome.
Chemoproteomics reveals that the sesquiterpene bigelovin covalently binds RACK1 at Cys168, disrupts RACK1–NLRP3 interactions, and blocks NLRP3 oligomerization across canonical, noncanonical, and alternative pathways. In murine models, bigelovin mitigated lung injury in LPS-induced ARDS and silicosis, positioning RACK1-mediated NLRP3 activation as a druggable anti-inflammatory node.
Impact: This study links a defined covalent interaction on RACK1 to suppression of NLRP3 activation and demonstrates in vivo efficacy in ARDS models, advancing both mechanistic understanding and therapeutic leads.
Clinical Implications: Suggests a novel anti-inflammatory strategy for NLRP3-driven lung diseases, including ARDS; however, translation to humans will require safety, selectivity, and pharmacokinetic evaluation.
Key Findings
- Bigelovin inhibited NLRP3 inflammasome activation and cytokine release via canonical, noncanonical, and alternative pathways at nanomolar concentrations.
- Chemoproteomics identified covalent binding of bigelovin to RACK1 Cys168, disrupting RACK1–NLRP3 interaction and suppressing NLRP3 oligomerization in vitro and in vivo.
- In murine models, bigelovin treatment alleviated lung disease severity in LPS-induced ARDS and silicosis.
- Findings consolidate RACK1’s role in transitioning NLRP3 from auto-suppressed to active oligomeric states and nominate RACK1 as a druggable node.
Methodological Strengths
- Chemoproteomic target deconvolution with covalent site mapping (Cys168 on RACK1).
- Cross-validation across canonical, noncanonical, and alternative inflammasome pathways with in vitro and in vivo efficacy.
Limitations
- Preclinical models only; human validation is lacking.
- Selectivity, off-target effects, and safety of covalent RACK1 engagement remain uncharacterized.
Future Directions: Optimize bigelovin-derived covalent modulators for selectivity and PK/PD, validate in primary human lung cells and ex vivo tissues, and test efficacy in infectious ARDS models.
Aberrant activation of the NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome contributes to the pathogenesis of fatal and perplexing pulmonary diseases. Although pharmacological inhibition of the NLRP3 inflammasome brings potent therapeutic effects in clinical trials and preclinical models, the molecular chaperones and transition governing its transformation from an auto-suppressed state to an active oligomer remain controversial. Here, this work shows that sesquiterpene bigelovin inhibited NLRP3 inflammasome activation and downstream pro-inflammatory cytokines release via canonical, noncanonical, and alternative pathways at nanomolar ranges. Chemoproteomic target identification discloses that bigelovin covalently bound to Cys168 of RACK1, disrupting the interaction between RACK1 and NLRP3 monomer and thereby suppressing NLRP3 inflammasome oligomerization in vitro and in vivo. Bigelovin treatment significantly alleviates the severity of NLRP3-related pulmonary disorders in murine models, such as LPS-induced ARDS and silicosis. These results consolidated the intricate role of RACK1 in transiting the NLRP3 state and provided a new anti-inflammatory lead and therapy for NLRP3-driven diseases.
2. Predicting Surfactant Need at Birth: Failed Validation of a Bedside Method Using Gastric Aspirates.
A prospective feasibility/validation study of a prototype bedside L/S ratio POC test using gastric aspirates in infants <30 weeks' gestation could not disclose diagnostic accuracy due to legal restrictions. Practical barriers—including absence of gastric aspirate and surfactant administration before sampling—limit clinical applicability and the ability to expedite treatment at birth.
Impact: Despite non-disclosure of accuracy, this study delivers valuable negative and feasibility data, cautioning against relying on gastric aspirate L/S POC testing for immediate surfactant decisions in very preterm infants.
Clinical Implications: Clinicians should continue to follow guideline-based criteria for surfactant administration rather than relying on gastric aspirate L/S POC testing at birth; alternative biomarkers or sampling strategies may be needed.
Key Findings
- Primary diagnostic accuracy and optimal L/S cut-off could not be reported due to legal restrictions.
- Among 93 eligible infants, 68 were included; 6% had no gastric aspirate available and 13% received surfactant before sampling.
- Overall, 62% received surfactant and 40% were treated within 2 hours of life (median 147 minutes; IQR 89–327), limiting opportunities for POC-guided decisions.
Methodological Strengths
- Prospective sampling within 45 minutes of birth with clinician blinding to L/S results.
- Use of standardized European RDS guidelines and prespecified ROC analysis framework.
Limitations
- Small single-prototype study with non-disclosure of the primary outcome due to legal restrictions.
- Feasibility constraints (missing gastric aspirates, early surfactant before sampling) and modest sample size (N=68).
Future Directions: Secure IP agreements prior to trials, explore earlier or alternative sampling matrices (e.g., tracheal aspirate, non-invasive biomarkers), and perform adequately powered multicenter validation.
AIM: To validate a prototype point-of-care (POC) test for the lecithin/sphingomyelin (L/S) ratio by identifying the optimal L/S cut-off for predicting surfactant need in preterm infants < 30 weeks' gestation using gastric aspirates (GAS) sampled at birth and to assess clinical feasibility. METHODS: GAS was sampled within 45 min of birth and analysed using the only available prototype POC L/S test. The primary outcome was the optimal L/S cut-off and diagnostic accuracy in predicting rescue surfactant treatment per European RDS guidelines, assessed by receiver operating characteristics. L/S results were blinded to clinicians. Due to a dispute between clinical investigators and patent holders, legal restrictions prohibit reporting of the primary outcome. RESULTS: Of 93 eligible infants, 25 were not included: Six cases (6%) had no GAS available, 12 infants (13%) received surfactant before sampling and 7 (8%) other reasons. Of 68 included, 42 (62%) received surfactant, and 40% were treated within 2 h of life (median: 147 min [IQR: 89; 327]). CONCLUSION: We aimed to validate a POC L/S test but are legally restricted from disclosing results. Clinical applicability seems limited, as a substantial proportion of infants had no GAS available or required surfactant before sampling. The potential to accelerate treatment appears limited.